Drug-Makers to Follow Scientific Standards for COVID-19 Vaccine
Nine leading American and European drug-makers promised to follow scientific standards in the race to develop an effective coronavirus vaccine.
The companies, including Pfizer, GlaxoSmithKline and AstraZeneca, made the promise after concerns were raised that safety standards might decline in the attempt to find a vaccine.
The companies said in a statement they would "uphold the integrity of the scientific process."
Other companies that signed the agreement included Johnson & Johnson, Merck & Co, Moderna, Novavax , Sanofi and BioNTech.
Ugur Sahin is head of BioNTech in Germany. He said "We want it to be known that also in the current situation we are not willing to compromise safety and efficacy."
The promise to play by established rules comes at a time of highly politicized debate. The debate is over what actions are needed to quickly control COVID-19 and increase international business and trade.
Governments race to approve vaccines
Last month, Russian President Vladimir Putin declared that Russia had become the first country to approve a vaccine for COVID-19. But some scientists question whether its quick approval will lead to a safe vaccine.
The head of China's Sinovac Biotech has also said most of its employees and their families have already taken an experimental vaccine. The vaccine, developed by the Chinese company, is part of the country's emergency-use program.
Chinese companies and organizations which are involved in developing COVID-19 vaccines did not sign the agreement.
Last week, the U.S. Centers for Disease Control and Prevention said COVID-19 vaccines could be approved by the Food and Drug Administration just days before the November 3 presidential election.
The announcement followed comments from President Donald Trump suggesting that the U.S. may have a vaccine before the election. Senator Kamala Harris, the Democratic Party's vice presidential nominee, said she would not take Trump's word alone on any possible coronavirus vaccine.
The drug-makers say approval for a COVID-19 vaccine must be based on trials of large groups of people from different ages, races and ethnic groups. The trials must compare similar groups that do not receive the vaccine in question. People taking part in the trial must not know which group they belong to.
BioNTech's Sahin said there must be statistical certainty of 95 percent - and in some cases higher - from the trials to show a positive result.
Michael Scholl is the chief executive of German vaccine developer Leukocare, which did not sign the promise. He said, "My biggest fear is that we will approve vaccines that are not safe." He noted that an unsafe vaccine will hurt the idea of vaccinations in general.
I'm John Russell.
The judge kept nodding in agreement.
An appeal court decided their convictions were unsafe.
I don't approve of violence in any shape or form.
There is too little certainty about the present state of the German economy.
5.The trials must compare similar groups that do not receive the vaccine in question.
in question 讨论中的；成问题的
The player in question is Mark Williams
I'm only worried about his attitude to the job; his competence is not in question.
6.the Democratic Party's vice presidential nominee, said she would not take Trump's word alone on any possible coronavirus vaccine.
take one's word 相信...的话
You'll buy nothing but trouble if you buy that house, take my word for it.
You can take his word for it. He has always been on the up and up.
乌格·萨因（Ugur Sahin）是德国BioNTech公司的负责人 。他表示，“我们想要告知外界，即便在当前局势下，我们也不愿意在安全性和有效性方面妥协 。”
遵守既定规则的承诺是在高度政治化辩论之际作出的 。这场辩论是关于需要采取哪些措施来快速控制新冠病毒并提升国际商贸 。
上个月，俄罗斯总统普京宣布俄罗斯成为首个批准新冠疫苗的国家 。但是一些科学家对其快速批准能否生产出安全的疫苗提出质疑 。
中国科兴控股生物技术有限公司的负责人也表示，该公司大多数员工及其家属已经接种了一种试验性疫苗 。这种由中国公司开发的疫苗是该国应急使用计划的一部分 。
在宣布这一消息之前，特朗普总统发表了评论，暗示美国可能会在大选前研发出疫苗 。参议员卡马拉·哈里斯（Kamala Harris）是民主党副总统提名人，她表示在新冠疫苗的可能性方面，她不会只听信特朗普的承诺 。
制药商表示，批准一种新冠疫苗，必须要经过对不同年龄、种族和族裔的大量人群进行试验 。试验必须与未接种相关疫苗的类似人群进行比对 。参与试验的人不能知道他们属于那个群体 。
迈克尔·肖尔是德国疫苗开发商Leukocare的首席执行官，该公司未签署该承诺 。他表示：“我最担心的是不安全疫苗会得到批准 。”他指出，不安全的疫苗一般都会损害疫苗接种的概念 。